Centre needs to work on war footing to deal Covishield side effects: AAP

In a press conference, Bharadwaj said that the Centre should talk to the vaccine manufacturing company, doctors and scientists for devising a mechanism to help people detect "warning signs or symptoms

Saurabh Bhardwaj
Delhi Health Minister Saurabh Bhardwaj. (Photo: PTI)
Press Trust of India New Delhi
2 min read Last Updated : May 01 2024 | 2:01 PM IST

Delhi Health Minister Saurabh Bharadwaj on Wednesday said there was need to deal with the "rare side effects" of Covishield vaccine on a war footing and alleged that the central government has done nothing so far in the matter.

In a press conference, Bharadwaj said that the Centre should talk to the vaccine manufacturing company, doctors and scientists for devising a mechanism to help people detect "warning signs or symptoms" of any side effects of the vaccine.

"This issue should not be politicised but the Centre has been sleeping and it has done nothing so far. This vaccine was banned in many European countries in 2021 when government in our country was administering and promoting it, " he said.

Bharadwaj said there were already questions in the minds of the people if the vaccine was in any way linked to the "sudden rise in heart attack cases".

There were numerous videos of people suddenly collapsing and dying during workouts and other such normal activities in different parts of the country.

UK-headquartered pharmaceutical giant AstraZeneca has admitted that in "very rare cases", its COVID-19 vaccine can cause a blood clot-related side-effect but the causal link is unknown, according to court papers being quoted in the UK media.

The Daily Telegraph reported that in a legal document submitted to the High Court in London in February for a group action brought by 51 claimants, AstraZeneca admitted that the vaccine developed with the University of Oxford to protect against COVID-19 may cause Thrombosis with Thrombocytopenia Syndrome (TTS) in "very rare cases".

The AstraZeneca Vaxzevria vaccine, also manufactured by the Serum Institute of India, was marketed in India as Covishield.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Delhi governmentAAPAam Aadmi PartyCoronavirus Vaccine

First Published: May 01 2024 | 2:00 PM IST

Next Story